Compare HIFS & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIFS | ANGO |
|---|---|---|
| Founded | 1834 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.4M | 530.2M |
| IPO Year | N/A | 2004 |
| Metric | HIFS | ANGO |
|---|---|---|
| Price | $279.15 | $10.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 87.7K | ★ 551.0K |
| Earning Date | 01-16-2026 | 01-06-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ 94.74 | N/A |
| EPS | ★ 20.54 | N/A |
| Revenue | $90,528,000.00 | ★ $307,306,000.00 |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | $14.70 | ★ N/A |
| Revenue Growth | ★ 54.99 | 7.26 |
| 52 Week Low | $209.71 | $8.27 |
| 52 Week High | $320.00 | $13.99 |
| Indicator | HIFS | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 30.25 |
| Support Level | $261.25 | $12.44 |
| Resistance Level | $303.55 | $13.37 |
| Average True Range (ATR) | 14.40 | 0.59 |
| MACD | -0.66 | -0.26 |
| Stochastic Oscillator | 42.32 | 11.18 |
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.